Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sobi Realigns Focus On Late-Stage Hematology & Immunology Assets

Jun 14 2019

• By Mike Ward

Business reengineering — Sobi reinforces Immunology focus

Related Content

New CEO Revamps Top Team, Specialty Care Business At Sobi

Oct 25 2017

Sobi Taps AstraZeneca's RSV Therapies, Both Current And Future, For US Expansion

Nov 13 2018

Sobi Advances Growth Strategy With Gamifant Launch In Early 2019 For Primary HLH

Nov 21 2018

Novimmune Sells Gamifant And IO Assets To Sobi

Jun 14 2019

Related Companies

Swedish Orphan Biovitrum AB

AstraZeneca PLC

Light Chain Bioscience

Amgen, Inc.

Additional Topics

Business Strategies Commercial Rare Diseases Strategy BioPharmaceutical Immune Disorders

More from Immunological

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.